

9th October 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1) How many patients received treatment for any condition in the last six months with any of the following treatment regimens (March 2026 – August 2026)?

•	Ocrevus (ocrelizumab) IV	0
•	Ocrevus (ocrelizumab) Subcutaneous	0
•	Kesimpta (ofatumumab)	0
•	Briumvi (ublituximab)	0
•	Mavenclad (cladribine)	0
•	Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	29
•	Vumerity (diroximel fumarate)	6
•	Tysabri (natalizumab) IV	0
•	Tysabri (natalizumab) Subcutaneous	0
•	Tyruko (natalizumab biosimilar)	0
•	Any Other Platform Therapies: (interferon Beta, peginterferon beta-1a, teriflunomide, glatiramoids)	35
•	S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)	0

Please note that, where the response above is '0', this indicates that the treatment is provided by University Hospitals Sussex NHS Foundation Trust (UHSussex). Their contact details are as follows:

By email: UHSussex.foi@nhs.net

- 1a) Of the patients identified in question one, how many of the same patients received treatment with each treatment regimen in November 2025-April 2026 AND March 2026 – August 2026)?

•	Ocrevus (ocrelizumab) IV	0
•	Ocrevus (ocrelizumab) Subcutaneous	0
•	Kesimpta (ofatumumab)	0
•	Briumvi (ublituximab)	0
•	Mavenclad (cladribine)	0
•	Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) – from November 2025 to April 2026	30
•	Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic) – from March 2026 to August 2026	29
•	Vumerity (diroximel fumarate) – from November 2025 to April 2026	5
•	Vumerity (diroximel fumarate – from March 2026 to August 2026	6
•	Tysabri (natalizumab) IV	0
•	Tysabri (natalizumab) Subcutaneous	0
•	Tyruko (natalizumab biosimilar)	0
•	Any Other Platform Therapies:	
•	Interferon Beta – from November 2025 to April 2026	16
•	Interferon Beta – from March 2026 to August 2026	13
•	Peginterferon beta-1a – from November 2025 to April 2026	1
•	Peginterferon beta-1a – from March 2026 to August 2026	1
•	Teriflunomide – from November 2025 to April 2026	12
•	Teriflunomide – from March 2026 to August 2026	10
•	Glatiramoids – from November 2025 to April 2026	14
•	Glatiramoids – from March 2026 to August 2026	11
•	S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)	0

Please note that, where the response above is '0', this indicates that the treatment is provided by University Hospitals Sussex NHS Foundation Trust (UHSussex). Their contact details are as follows:

By email: UHSussex.foi@nhs.net

- 2) How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (March 2026 – August 2026)?

28.

2a) Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

•	Ocrevus (ocrelizumab) IV	0
•	Ocrevus (ocrelizumab) Subcutaneous	0
•	Kesimpta (ofatumumab)	0
•	Briumvi (ublituximab)	0
•	Mavenclad (cladribine)	0
•	Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	29
•	Vumerity (diroximel fumarate)	6
•	Tysabri (natalizumab) IV	0
•	Tysabri (natalizumab) Subcutaneous	0
•	Tyruko (natalizumab biosimilar)	0
•	Any Other Platform Therapies:	
•	Interferon Beta	12
•	Peginterferon beta-1a	1
•	Teriflunomide	19
•	Glatiramoids)	12
•	S1P Receptor Modulators (fingolimod, siponimod, ponesimod, ozanimod)	0

Please note that, where the response above is '0', this indicates that the treatment is provided by University Hospitals Sussex NHS Foundation Trust (UHSussex). Their contact details are as follows:

By email: UHSussex.foi@nhs.net

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
 East Sussex Healthcare NHS Trust
 0300 131 4716
 Core Hours of Business: Monday to Friday 9.00am to 4.00pm